Polyrizon Reports Positive Preclinical Results for PL-14 Allergy Blocker
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Source: Globenewswire
- Efficacy Validation: The PL-14 formulation significantly reduced the transfer of the major allergen Der p 1 compared to the standard comparator HPMC, with allergen concentrations at 1 hour being approximately 20.6 ng versus HPMC's 1354.4 ng, indicating its potential as a new preventive solution for allergic rhinitis.
- Sustained Protective Effect: At 4 hours, PL-14 reached a maximum allergen concentration of about 141.2 ng while maintaining low levels across all time points, demonstrating its sustained protective capability against allergen exposure to nasal tissue, which enhances its market competitiveness.
- R&D Advancement: The study utilized a validated in-vitro permeability system, ensuring data reliability and supporting further development of PL-14 as a potential preventive approach for allergic rhinitis, potentially laying the groundwork for future clinical studies.
- Market Potential: Polyrizon plans to continue advancing PL-14's preclinical development to establish its regulatory pathway and real-world clinical benefits, reflecting the company's commitment to the allergy market and its long-term growth potential.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like PLRZ with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on PLRZ
About PLRZ
Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers..
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Polyrizon Ltd. Explores Strategic Investments in Aviation, AI, and Defense Sectors
- Strategic Investment Exploration: Polyrizon's Board has authorized the exploration of strategic investment opportunities in high-potential sectors, particularly in defense, aviation, and artificial intelligence, aiming to generate near-term revenues and enhance financial stability through selective investments.
- Commitment to Core Medical: The company remains focused on its core medical device activities, advancing the development and clinical studies of products like PL-14 (allergy blocker) and PL-16 (viral blocker), ensuring ongoing innovation and competitiveness in the medical field.
- Strong Financial Position: With a robust cash flow and a debt-free balance sheet, Polyrizon is well-positioned to efficiently utilize resources to accelerate growth and create long-term shareholder value while maintaining full focus on its primary medical pipeline.
- Technological Innovation Development: Polyrizon is developing its proprietary Capture and Contain TM hydrogel technology, which aims to provide a barrier against viruses and allergens through nasal sprays, further enhancing its market position in the biomedical field.
Continue Reading
Polyrizon (PLRZ) Reports Positive Preclinical Results for PL-14 Allergy Blocker
- Preclinical Study Results: Polyrizon's PL-14 Allergy Blocker demonstrated significant allergen-blocking performance in a new in-vitro study, effectively reducing allergen transfer compared to hydroxypropyl methylcellulose (HPMC) at all time points, indicating its potential to form an effective intranasal hydrogel barrier that minimizes allergen exposure to nasal tissue.
- Advancement of Development Program: Following these positive results, the company plans to advance its preclinical development program and support future clinical studies aimed at establishing PL-14's regulatory pathway and real-world clinical benefits for allergy prevention, positioning it as a viable solution in the market.
- Positive Market Reaction: In response to the favorable news, Polyrizon's stock rose 5.65% to $13.47 on Nasdaq, reflecting investor confidence in the company's research progress and market potential.
- Strategic Implications: The successful development of PL-14 could not only transform the landscape of allergy treatment but also enhance Polyrizon's competitiveness in the biopharmaceutical sector, further driving the company's positioning in the allergy prevention market.
Continue Reading